Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy

Vascular Pharmacology

Volumn 47, Issue 2-3, 2007, Pages 113-117

  Nieminen, Tuomo ^a   Knuuti, Juhani ^b   Hämelahti, Päivi ^b   Kähönen, Mika ^c   Laaksonen, Reijo ^b,d   Janatuinen, Tuula ^c   Vesalainen, Risto ^c   Nuutila, Pirjo ^c   Jokela, Hannu ^b   Lehtimäki, Terho ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cholesterol; Coronary circulation; Homocysteine; Methylenetetrahydrofolate reductase; Positron emission tomography

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE; HOMOCYSTEINE; PRAVASTATIN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BLOOD FLOWMETRY; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOSINE; ADULT; ANTICHOLESTEREMIC AGENTS; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; PRAVASTATIN;

EID: 34547113361     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.05.001     Document Type: Article

References (26)

1. Aguilar B., Rojas J.C., and Collados M.T. Metabolism of homocysteine and its relationship with cardiovascular disease. J. Thromb. Thrombolysis. 18 (2004) 75-87
2. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., Lehmann J., Heitzer T., Yla-Herttuala S., Luoma J., Kurz S., Munzel T., Just H., Olschewski M., and Drexler H. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
3. Capecchi P.L., Lazzerini P.E., Maccherini M., Guideri F., Lisi G., Acampa M., Cuomo A., Diciolla F., Toscano M., and Laghi Pasini F. Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients. Transplant. Proc. 34 (2002) 1273-1274
4. Demuth K., Moatti N., Hanon O., Benoit M.O., Safar M., and Girerd X. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1838-1843
5. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
6. Fruchart J.C., Nierman M.C., Stroes E.S., Kastelein J.J., and Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 109 (2004) III15-III19
7. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., and Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154 (2001) 421-427
8. Girelli D., Friso S., Trabetti E., Olivieri O., Russo C., Pessotto R., Faccini G., Pignatti P.F., Mazzucco A., and Corrocher R. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 91 (1998) 4158-4163
9. Haak E., Abletshauser C., Weber S., Goedicke C., Martin N., Hermanns N., Lackner K., Kusterer K., Usadel K.H., and Haak T. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 155 (2001) 395-401
10. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (2005) 1685-1695
11. Iida H., Rhodes C.G., de Silva R., Araujo L.I., Bloomfield P.M., Lammertsma A.A., and Jones T. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J. Nucl. Med. 33 (1992) 1669-1677
12. Laaksonen R., Janatuinen T., Vesalainen R., Lehtimaki T., Elovaara I., Jaakkola O., Jokela H., Laakso J., Nuutila P., Punnonen K., Raitakari O., Saikku P., Salminen K., and Knuuti J. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur. J. Clin. Investig. 32 (2002) 795-802
13. Laine H., Raitakari O.T., Niinikoski H., Pitkänen O.P., Iida H., Viikari J., Nuutila P., and Knuuti J. Early impairment of coronary flow reserve in young men with borderline hypertension. J. Am. Coll. Cardiol. 32 (1998) 147-153
14. MacMahon M., Kirkpatrick C., Cummings C.E., Clayton A., Robinson P.J., Tomiak R.H., Liu M., Kush D., and Tobert J. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10 (2000) 195-203
15. Malik J., Melenovsky V., Wichterle D., Haas T., Simek J., Ceska R., and Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc. Res. 52 (2001) 290-298
16. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337 (1997) 230-236
17. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Faergeman O., Faergeman G., Pyorala K., Miettinen T., Wilhelmsen L., Olsson A.G., and Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler. Suppl. 5 (2004) 81-87
18. Pereira E.C., Bertolami M.C., Faludi A.A., Sevanian A., and Abdalla D.S. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients. Free Radic. Biol. Med. 37 (2004) 1440-1448
19. Pitkänen O.P., Nuutila P., Raitakari O.T., Porkka K., Iida H., Nuotio I., Ronnemaa T., Viikari J., Taskinen M.R., Ehnholm C., and Knuuti J. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 99 (1999) 1678-1684
20. Ridker P.M., Shih J., Cook T.J., Clearfield M., Downs J.R., Pradhan A.D., Weis S.E., and Gotto Jr. A.M. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 105 (2002) 1776-1779
21. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., and Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb. Haemost. 92 (2004) 1129-1135
22. Sunder-Plassmann G., and Fodinger M. Genetic determinants of the homocysteine level. Kidney Inter., Suppl. (2003) S141-S144
23. Todesco L., Angst C., Litynski P., Loehrer F., Fowler B., and Haefeli W.E. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. Eur. J. Clin. Investig. 29 (1999) 1003-1009
24. Ulvik A., Refsum H., Kluijtmans L.A., and Ueland P.M. C677T mutation of methylenetetrahydrofolate reductase gene determined in blood or plasma by multiple-injection capillary electrophoresis and laser-induced fluorescence detection. Clin. Chem. 43 (1997) 267-272
25. Verhoef P., and de Groot L.C. Dietary determinants of plasma homocysteine concentrations. Semin. Vasc. Med. 5 (2005) 110-123
26. Yamashita K., Tasaki H., Nagai Y., Suzuka H., Nihei S., Kobayashi K., Horiuchi M., Nakashima Y., and Adachi T. Experimental hyperhomocysteinemia impairs coronary flow velocity reserve. Int. J. Cardiol. 104 (2005) 163-169